Product Authorisation
description
Transcript of Product Authorisation
Product Authorisation
Workshop on REACH and EU Biocidal Product Legislation in practice(Experiences from EU Industry)INT MARKT 48493Belgrade, Serbia
Raf Bruyndonckx1 June 2012
Procedures and Requirements
Outline
• General principles
• Procedures
• Application
• Data requirements
• Fees
• Role of industry associations
2
Cefic
3
• Cefic – European Chemical Industry Council
• Membership• 28 national chemical federations• > 600 companies• > 20 affiliated sector associations
• Horizontal - vertical• EU Policy Centre: REACH, International trade,
energy and climate change, HSE, logistics, R&I …• 104 Sector Groups
EBPF
4
• European Biocidal Products Forum
• Sector group of Cefic
• Regulatory developments of EU biocides legislation• AS producers & BP formulators• 70 members: companies, associations, federations
• Recognised stakeholder & observer
• Implementation BPD: AS evaluation – BP authorisation
• New Regulation
EBPF – European Biocidal Products Forum
BPR - New era starting Sep 2013
• Updated EU biocides law applicable 1 Sep 2013• Regulation – directly applicable to all EU• Same principles, improved procedures – mutual
recognition, changes to products• New concepts – EU authorisation, product family• Extended scope – treated articles• European Chemicals Agency
6
Abbreviations
• BPD Biocidal Product Directive 98/8/EC• BPR Biocidal Product Regulation• AS active substance• BP biocidal product• PT product type• PA product authorisation• MR mutual recognition• LoA letter of access• MS member state(s)
7
Product Authorisation
General Principles
8
General principles
9
• Authorisation is required before placing on the market
• Authorisation is granted for max. 10 years
• Authorisation can be granted if all conditions are fulfilled:• AS is approved for relevant PT + AS source is on positive list• The product is effective• No unacceptable effects on target organism (resistance)• No unacceptable effects on HH, ENV or animal health• Chemical identity is known (impurities/residues)• Phys-chem properties acceptable for transport and use
General principles
10
• A BP cannot be authorised for use by general public if:• It is classified acute tox. (dermal, oral, inhalation);• It is classified CMR 1 or 2;• It has PBT properties;• It has endocrine disrupting properties or• It has developmental neurotoxic or immunotoxic
effects
General principles
11
• Dossier elements:• AS data: LoA or complete dossier• BP data: complete dossier (or LoA)• Assessment of hazard, risk (through relevant
exposure) and efficacy• Draft Summary of the biocidal Product Characteristics
(SPC)
SPC – the ID card of a BP
12
• Trade name
• Authorisation holder – authorisation number
• Date of authorisation & expiry date
• Manufacturer of BP and AS
• Qualitative and quantitative composition
• Type of formulation – categories of users
• Instructions for use and safe disposal
Product Authorisation
Procedures
13
Different procedures
14
• (National) authorisation – provisional authorisation• Mutual recognition (in parallel or in sequence)BPR:
• Union authorisation• Coordination by ECHA, evaluation by MS, decision by
COM
• Simplified authorisation procedure
• Parallel trade authorisation
• “Same product” authorisation
Timelines
15
• 2 years to submit dossier
• 2 years to grant, amend or withdraw authorisations
• 3 months for completeness check
• 12 months for first authorisation
• 2 months to apply for mutual recognition
• 4 months to recognise first authorisation
• 3 months to resolve diverging opinions
31/12/101/01/07 1/01/098/09/06
3 monthscompleteness
check(01/01 to 31/03/09)
2 monthsapplication for
mutual recognition
(01/04 to 31/05/10)
12 months1st evaluation and authorisation
(01/04/09 to 31/03/10)
4 monthsrecognition of
1st authorisation(01/06 to 30/09/10)
3 months(01/10 to 31/12/10)
††
No application/notification (30/06/09)
Failed completeness check (30/09/09)
Timelines
16
Union authorisation - scope
17
• Valid across all MS at once
• Similar conditions of use across the Union - guidance
• Excluded: Art 5 – PTs 14, 15, 17, 20 and 21
• Sep 2013: new AS - PTs 1, 3, 4, 5, 18 and 19
• Jan 2017: PTs 2, 6 and 13
• Jan 2020: all categories
• Assessment report by 31 Dec 2017
18
• Conditions: AS in Annex I (BPR), no SoC, no nano, no
PPE, sufficiently efficient
• No requirement for a LoA to AS dossier
• Submission to the Agency
• Evaluation by a MS within 90 days
• Once authorised, notification to other MS is sufficient –
no MR
Simplified authorisation procedure
“Same product” authorisations
19
• Identical products• Existing practice (NL, FI, CH, SE, DK, PT, BE, IT ...)
• Mutual recognition within a MS between companies
• Faster procedures
• Principle in BPR, follow-up regulation
Product Authorisation
Application
20
R4BP
21
• Register for Biocidal Products
• Electronic database – “EU catalogue of products”
• Application form – Applicant & product
• Decision and assessment report
BPR:
• Electronic submissions – no more paper
• Central communication and process management tool
• Covers both AS and BP
R4BP
22
Product Authorisation
Data requirements
23
General outline
24
• Data on the active substance(s) – LoA to Annex I dossier
• Substances of concern
• Data on the biocidal product
• Use description – exposure assessment
• Analytical methods
• Properties/Effect/hazard assessment (PC, TOX, ENV)
• Risk assessment
• Efficacy
25
Doc. IV-A or LoA*: Test and Study Reports
a.s.(s)
Doc. IV-B or LoA*: Test and Study Reports
b.p.**
Doc II-B or LoA* - Effects
Assess.** - Exposure Assess.
- Efficacy Assess.
for Biocidal Prod.2)
Doc II-A or LoA*
Effects and exposure Ass.
Active Subst.(s)2)
Doc. II-C Risk Characterisation for Biocidal Product
Doc. II Risk and Efficacy Assess.
Doc. I Overall
Summary and Assessment1)
Document III-A or LoA*
Study Summaries Active Substance(s)2)
Document III-B or LoA*: Study Summaries Biocidal Product2)
1) To append: List of end points 2) To append: Reference lists List of abbreviations Check for completeness
Summary Dossier
Complete Dossier
Data waiving
26
• A data requirement is not relevant to the product and/or
the intended use
• A study cannot be performed because the test is not
feasible
• The outcome of a study can be accurately predicted
based on a scientific argumentation
• The outcome of the study is in no way relevant to the risk
assessment, classification and labelling or intended use
Principle approach
27
• Collate info on components - AS and SoC
• Start with detailed use description
• Derive possible exposure (exclude specific routes)
• Properties/Effect/hazard assessment
• Risk assessment – Risk reduction measures
• Efficacy
Availability of data
28
• Active substance dossier (LoA required)
• Co-formulants: REACH – MSDS
• Public literature
Product Authorisation
Fees
29
Fees
30
• Broad variation across MS
• First authorisation: 10.000 – 50.000 Euro
• Changes: 500 – 25.000 Euro
• Renewal: 500 – 50% of original fee
• Annual fee: fixed or related to sales
Role of industry associations
31
Role of industry associations
32
• General representation of industry
• Endeavour to be recognised stakeholder
• Consensus driven position taking
• Competition law considerations
• No specific role regarding data sharing
Useful sources of information
33
• Note for guidance to applicants for PA and MR - link
• EU Evaluation Manual - link
• TNsG on data requirements – link
• TNsG on product evaluation – link
• Joint Research Centre – biocides section - link
Raf Bruyndonckx+32 2 676 7366